OVID
OVID
NASDAQ · Biotechnology

Ovid Therapeutics Inc

$2.26
+0.04 (+1.80%)
Financial Highlights (FY 2025)
Revenue
29.94M
Net Income
-8,740,072
Gross Margin
35.9%
Profit Margin
-29.2%
Rev Growth
-9.8%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 35.9% 35.9% 35.9%
Operating Margin -30.9% -33.9% -31.3%
Profit Margin -29.2% -26.8% -31.1%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 29.94M 31.11M 33.06M
Gross Profit 10.74M 11.16M 11.86M
Operating Income -9,244,305 -10,543,713 -10,340,763
Net Income -8,740,072 -8,350,078 -10,285,734
Gross Margin 35.9% 35.9% 35.9%
Operating Margin -30.9% -33.9% -31.3%
Profit Margin -29.2% -26.8% -31.1%
Rev Growth -9.8% +19.5% +23.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 30.67M 32.20M 24.28M
Total Equity 123.93M 114.62M 121.51M
D/E Ratio 0.25 0.28 0.20
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -14,130,650 -13,566,183 -16,328,398
Free Cash Flow -7,098,906 -8,976,737 -6,780,942